it'll drop off. the revenue growth of 15% with no profit despite the already 1.5billion addressable market suggests limited traction going forward. Adding additional addressable market isnt resulting in much cumulative growth in its history so far. Addressable markets have limited applicability to medicine anyway, as medicine is subjective.
This is no Polynovo or Avita medical, which had 100-200% huge revenue growth(prior to covid-19). Avita has gone off the boil completely. This has not even a tenth of that growth and prospects.
- Forums
- IPOs
- Aroa Biosurgery IPO
it'll drop off. the revenue growth of 15% with no profit despite...
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online